Nurix Therapeutics shares are trading lower after the company announced that it commenced a $125 million underwritten public offering.
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics has initiated a $125 million underwritten public offering, leading to a decrease in its share price.
April 11, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nurix Therapeutics' decision to start a $125 million underwritten public offering has resulted in a decline in its share price.
Public offerings often lead to a dilution of existing shares, causing a negative short-term impact on the stock price. Given the size of the offering relative to the company, this move is likely to have a significant impact on Nurix Therapeutics' share price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100